IBM (NYSE:IBM | IBM Price Prediction) at $234.32 is a Buy. The stock has rebounded 11.74% in the last month off a mid-July capitulation, and the drivers of that rebound remain intact.
IBM is a hybrid-cloud and enterprise-AI franchise wrapped around one of the most durable software and mainframe installed bases in technology. Software is now roughly 45% of total revenue, with Red Hat, Data, Automation, and transaction-processing software running on IBM Z. The stock is down from a 52-week high of $330.09 after a rough Q2 shook confidence in the AI growth story.
Why The Franchise Case Is Getting Stronger
The engine is accelerating where it matters. In Q2 2026, Red Hat grew 11%, Data grew 19%, and Distributed Infrastructure posted its best quarter on record at 37% growth with a $500 million backlog. Software ARR reached $24.6 billion, up 8% YoY, with 80% of software revenue now recurring.
The generative-AI book of business is real, crossing $12.5 billion inception-to-date. Combining IBM watsonx with Red Hat OpenShift gives enterprises a single platform for AI and application lifecycles across hybrid, public, and on-premises environments, lowering operational costs and preventing vendor lock-in. Management also committed more than $10 billion to quantum over five years, with Starling, the first large-scale fault-tolerant machine, targeted for 2029. And IBM raised full-year revenue guidance to 4% to 5% constant-currency growth despite the Q2 stumble.
Why Bears See A Value Trap
Q2 broke a five-quarter beat streak with EPS of $2.93 versus $2.97 expected. Infrastructure fell 7.4%, with IBM Z mainframe revenue collapsing 42% as the cycle troughed. Operating income dropped 19.67% YoY, Consulting grew just 0.2%, and cash and equivalents fell 39.95% YoY.
Overhanging all of it is a securities fraud inquiry into pipeline disclosures, which makes every forward comment from management harder to underwrite. Polymarket traders priced this correctly, with the Q2 EPS-beat market closing at $0.001 and every software-revenue threshold above $7.9B resolving No.
Why Patience Has Its Own Cost
The hold case is that the mainframe cycle has not clearly inflected, Consulting has not reaccelerated, and the pipeline inquiry is unresolved. Waiting for a clean quarter is defensible. The cost of patience is that the highest-conviction data points, Red Hat, Data, Distributed Infrastructure backlog, and the AI book, are already visible, and free cash flow surged 70.36% YoY in Q2.
What The Numbers Say At This Price
IBM trades at $234.32 against an analyst consensus target of $244.16, implying modest upside. Targets are one input among many. Coverage spans 25 analysts: 3 Strong Buy, 11 Buy, 9 Hold, 1 Sell, 1 Strong Sell. Forward P/E sits at 19, below the trailing 21, with a 2.84% dividend yield and 31 consecutive years of dividend increases.
Shares are down 19.28% year-to-date, materially trailing the S&P 500, which is positive over the same stretch. Over five years IBM is up 107.55%.
The Verdict At $234
At $234, IBM is a Buy. Here is why.
The path to appreciation runs through three catalysts landing inside twelve months: the mainframe cycle bottoming and reverting toward the 130% Z17 program-to-program pace, software recurring revenue accelerating from 8% toward 10%, and the slipped Q2 capex deals closing, of which roughly one-third have already closed in the first three weeks of Q3.
At a forward P/E of 19 with a 2.84% yield and a 0.705 beta, the risk/reward skews favorably. The thesis breaks if the securities inquiry produces material findings, if Consulting cannot escape 0% growth, or if the mainframe base actually shrinks. Watch quarterly software ARR, distributed-infrastructure backlog, and Consulting signings growth beyond the current 6%.
Buying IBM at $234 buys franchise assets during a cycle trough at a value multiple.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks